Evidence map›Paper›PMID 21426260›Full record

ReviewExpert review of clinical immunology2011

Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Maureen McMahon, Bevra H Hahn, Brian J Skaggs

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of clinical immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Cardiac Involvement in Systemic Lupus Erythematosus.Reviews in cardiovascular medicine · 2025
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Maureen McMahonDivision of Rheumatology, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA. mmcmahon@mednet.ucla.edu
Bevra H Hahn
Brian J Skaggs

Funding

The Role of Monocytes in SLE-related Accelerated AtherosclerosisK01AR059095 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SKAGGS, BRIAN J · 2010 to 2014
$695k
Pro-Inflammatory HDL as a Novel Target for the Indentification of AtherosclerosisK23AR053864 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCMAHON, MAUREEN A · 2007 to 2011
$625k
NIAMS NIH HHS 1K23AR053864-01A1NIAMS NIH HHS K01 AR059095NIAMS NIH HHS K23 AR053864
6 · The paper itself

Abstract

Patients with systemic lupus erythematosus have a significantly increased risk of cardiovascular events due to atherosclerosis. Traditional cardiac risk factors cannot fully explain this increased risk. Recent evidence strongly suggests that atherosclerotic plaque is largely driven by inflammation and an active immunological response, in contrast to the long-held belief that plaque is a passive accumulation of lipids in the arterial wall. Current approaches to the prevention of atherosclerosis in systemic lupus erythematosus involve targeting modifiable cardiac risk factors. Future preventive strategies may include therapies that counteract the immunologic responses that lead to plaque formation.

Indexed as

Apolipoprotein A-IBiological TherapyBiomimeticsCardiovascular DiseasesHumansInflammationLupus Erythematosus, SystemicLymphocyte DepletionPlaque, AtheroscleroticRisk FactorsApolipoprotein A-I

Identifiers

PMID21426260
PMCPMC3718673

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.